Vasoplegia clinical trials at UCSF

1 research study open to eligible people

Vasoplegia means blood vessels cannot tighten, causing blood pressure to drop. At UCSF, researchers are examining if Angiotensin II can safely help during liver transplants. This trial looks at the drug as a second-line option to manage blood pressure.

Showing trials for

  • Angiotensin II in Liver Transplantation

    open to eligible people ages 18 years and up

    The purpose of this study is to determine the efficacy and safety of Angiotensin II as a second-line vasopressor (drug that raises the blood pressure) during liver transplantation.

    San Francisco, California

Our lead scientists for Vasoplegia research studies include .

Last updated: